Pharma companies are pretty sure about the identity of many of the products on the upcoming Centers for Medicare and Medicaid Services list of the 10 drugs chosen for Medicare Part D price negotiation. But ongoing patent litigation and a lack of publicly available data on current program spending has created uncertainties about others.
Medicare Price Negotiation List Remains A Puzzle, Even For Those That Are (Probably) On It
Highly anticipated list will determine the Medicare Part D drugs subject to negotiated prices in 2026. Under the law, the list cannot be subject to administrative or judicial review, so the stakes are high. As patent and sales statuses shift, the Pink Sheet offers a baker's dozen of possible drugs.
